Literature DB >> 7841736

A prospective study of the adverse effects of midazolam on withdrawal in critically ill children.

J Hughes1, A Gill, H J Leach, A J Nunn, I Billingham, J Ratcliffe, R Thornington, I Choonara.   

Abstract

Fifty-three critically ill infants and children received midazolam as sedation in a regional intensive care unit. Assessment of the level of sedation was carried out at regular intervals on withdrawal of midazolam. Forty-nine patients were fully alert within 4 h of midazolam being stopped. Four patients took from 6 h to 1 week to become fully alert. Four patients had abnormal behaviour highly suggestive of midazolam withdrawal. The onset of abnormal behaviour was within 12 h of discontinuation of midazolam. The duration of the abnormal behaviour ranged from 3 h to 1 week. One child had a paradoxical reaction to midazolam. The overall incidence of adverse effects to midazolam in the patients studied was 17%. No adverse effects were observed in infants; all adverse effects were observed in children. We have shown that it is possible to prospectively study the toxicity of sedatives in critically ill infants and children.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7841736     DOI: 10.1111/j.1651-2227.1994.tb18280.x

Source DB:  PubMed          Journal:  Acta Paediatr        ISSN: 0803-5253            Impact factor:   2.299


  22 in total

Review 1.  Drug trials in children: problems and the way forward.

Authors:  S Conroy; J McIntyre; I Choonara; T Stephenson
Journal:  Br J Clin Pharmacol       Date:  2000-02       Impact factor: 4.335

Review 2.  Sedation and analgesia in paediatric intensive care units: a guide to drug selection and use.

Authors:  J D Tobias
Journal:  Paediatr Drugs       Date:  1999 Apr-Jun       Impact factor: 3.022

3.  Tolerance to sedative drugs in PICU: can it be moderated or is it immutable?

Authors:  Andrew R Wolf; Bronagh Blackwood; Brian Anderson
Journal:  Intensive Care Med       Date:  2015-11-24       Impact factor: 17.440

4.  Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.

Authors:  Lise Aagaard; Lars Hougaard Nielsen; Ebba Holme Hansen
Journal:  Drug Saf       Date:  2009       Impact factor: 5.606

5.  Midazolam Responsive Oculogyric Crisis, Oral Automatisms, Akinesia and Rigidity Induced by Sedation Withdrawal in a Child.

Authors:  Robertino Dilena; Alberto Giannini; Alberto Cappellari; Sophie Guez; Alberto Priori
Journal:  Mov Disord Clin Pract       Date:  2014-06-06

Review 6.  Risk factors associated with iatrogenic opioid and benzodiazepine withdrawal in critically ill pediatric patients: a systematic review and conceptual model.

Authors:  Kaitlin M Best; Joseph I Boullata; Martha A Q Curley
Journal:  Pediatr Crit Care Med       Date:  2015-02       Impact factor: 3.624

7.  Consensus guidelines on sedation and analgesia in critically ill children.

Authors:  Stephen Playfor; Ian Jenkins; Carolyne Boyles; Imti Choonara; Gerald Davies; Tim Haywood; Gillian Hinson; Anton Mayer; Neil Morton; Tanya Ralph; Andrew Wolf
Journal:  Intensive Care Med       Date:  2006-05-13       Impact factor: 17.440

8.  Feasibility of sedation and analgesia interruption following cannulation in neonates on extracorporeal membrane oxygenation.

Authors:  E D Wildschut; M N Hanekamp; N J Vet; R J Houmes; M J Ahsman; R A A Mathot; S N de Wildt; D Tibboel
Journal:  Intensive Care Med       Date:  2010-05-28       Impact factor: 17.440

9.  Impact of a Standardized Treatment Guideline for Pediatric Iatrogenic Opioid Dependence: A Quality Improvement Initiative.

Authors:  Rima Abdouni; Teri Reyburn-Orne; Tarek H Youssef; Imad Y Haddad; Richard D Gerkin
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Jan-Feb

Review 10.  [Neurotoxicity of general anesthetics in childhood: does anesthesia leave its mark on premature babies, newborns and infants?].

Authors:  B Sinner; K Becke; K Engelhard
Journal:  Anaesthesist       Date:  2013-02       Impact factor: 1.041

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.